Clovis rolls with rociletinib NDA in lung cancer
This article was originally published in Scrip
Executive Summary
Clovis Oncology is seeking the FDA's blessing on the firm's investigational drug rociletinib as a treatment non-small-cell lung cancer (NSCLC) – initiating a rolling new drug application, which the company said it plans to complete by the end of this month.